TherapeuticsMD, Inc. (NASDAQ:TXMD – Get Free Report) was the recipient of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 12,000 shares, a decrease of 43.7% from the December 15th total of 21,300 shares. Based on an average daily volume of 275,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.1% of the shares of the company are sold short.
TherapeuticsMD Stock Up 0.9 %
Shares of TherapeuticsMD stock traded up $0.01 on Thursday, reaching $1.12. 10,232 shares of the company traded hands, compared to its average volume of 1,638,088. The company has a 50 day moving average of $1.25 and a 200 day moving average of $1.54. TherapeuticsMD has a 52 week low of $0.70 and a 52 week high of $2.75.
Wall Street Analysts Forecast Growth
Separately, StockNews.com assumed coverage on shares of TherapeuticsMD in a report on Tuesday. They issued a “hold” rating on the stock.
Institutional Trading of TherapeuticsMD
A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP increased its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) by 18.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the period. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities and Exchange Commission. 30.74% of the stock is owned by hedge funds and other institutional investors.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Further Reading
- Five stocks we like better than TherapeuticsMD
- How to Most Effectively Use the MarketBeat Earnings Screener
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What Are Dividend Achievers? An Introduction
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
